Progenics Pharma (PGNX) Gets Go-Ahead Recommendation; Mizuho Eyeing Opportunity in Sucampo Pharma (SCMP)
Shares of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) surged more than 6% in after-hours trading Thursday as the company said that a Data Monitoring Committee recommended the continuation of the ongoing late-stage clinical trial evaluating its PSMA-targeted imaging agent 99mTc-MIP-1404 for prostate cancer.
PGNX stock finished the regular session at $8.86, down $0.02 (or -0.23%) and 413,275 of its shares changed hands during the day.
Progenics, which is engaged in developing medicines and other products for targeting and treating cancer, has 70.05M shares outstanding, market capitalization (intraday) of $622.06M and PGNX stock 52-week range is from $3.61 to $9.54 per share
Brokerage firm Mizuho upgraded Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) shares from a Neutral to a Buy rating with a price target of $16.00
The company’s stock surged 2.33% (or +$0.30) to $13.15 with a total volume of 2.20M shared traded on Thursday, representing a large increase in activity versus its average volume (3m) of 1.09M shares.
Sucampo Pharmaceuticals, which focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders, has 45.83M shares outstanding, market capitalization (intraday) of $583.46M and SCMP stock one-year range is between $9.59 and $18.75 per share.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/